Data updated: Mar 10, 2026
TRUSELTIQ
INFIGRATINIB PHOSPHATE
Approved 2021-05-28
1
Indication
--
Phase 3 Trials
1
Priority Reviews
4
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2021-05-28
- Routes
- ORAL
- Dosage Forms
- CAPSULE
TRUSELTIQ Approval History
Loading approval history...
What TRUSELTIQ Treats
1 FDA approvalsOriginally approved for its first indication in 2021 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TRUSELTIQ FDA Label Details
ProTRUSELTIQ Patents & Exclusivity
Latest Patent: Dec 2034
Exclusivity: May 2028
Patents (16 active)
US10278969
Expires Dec 11, 2034
US11160804
Expires Dec 11, 2034
US8552002
Expires Aug 25, 2029
US9067896
Expires Aug 6, 2028
+ 6 more patents
Exclusivity
NCE
Until May 2026
ODE-353
Until May 2028
NCE
Until May 2026
ODE-353
Until May 2028
NCE
Until May 2026
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.